Fig. 1: Lorlatinib is predicted to bind to LTK and ALK. | Communications Biology

Fig. 1: Lorlatinib is predicted to bind to LTK and ALK.

From: LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

Fig. 1

a Schematic representation of LTK and ALK protein. LTK and ALK are formed with three regions: extracellular, transmembrane, and intracellular region. They consist of 864 amino acids (aa) and 1620 aa respectively. MAM, meprin, A-5 protein, and receptor protein-tyrosine phosphatase μ domain; LDLa, low-density lipoprotein class A motif; Gly_rich, glycine rich region; TM, transmembrane region. b The lorlatinib-binding mode for the LTK kinase domain. The protein is depicted by a surface model (I565, blue; L590, red; L592, orange; G596, cyan; D597, yellow; L650, magenta; others, gray) and lorlatinib is depicted by sticks (C, green; N, blue; and O, red). An enlarged view of the ATP-binding pocket is shown in the left panel. In the right panel, hydrogen bonds between LTK residues (E591 and M593) and lorlatinib are shown as dashed yellow lines.

Back to article page